Human pregnancy safety for agents used to treat rheumatoid arthritis: Adequacy of available information and strategies for developing post-marketing data

Arthritis Research and Therapy

Volumn 8, Issue 4, 2006, Pages

  Chambers, Christina D ^a,b   Tutuncu, Zuhre N ^c   Johnson, Diana ^a   Jones, Kenneth L ^a  

^a UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; ANTIRHEUMATIC AGENT; AZATHIOPRINE; CELECOXIB; CHLORAMBUCIL; CORTICOSTEROID; CORTICOSTEROID DERIVATIVE; CORTISONE; CYCLOPHOSPHAMIDE; CYCLOSPORIN; DICLOFENAC; ETANERCEPT; HYDROXYCHLOROQUINE; IBUPROFEN; INDOMETACIN; INFLIXIMAB; KETOPROFEN; KETOROLAC; LEFLUNOMIDE; METHOTREXATE; NAPROXEN; NIMESULIDE; NONSTEROID ANTIINFLAMMATORY AGENT; PIROXICAM; PREDNISONE; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; RITUXIMAB; SALAZOSULFAPYRIDINE; SULFALAZINE; UNINDEXED DRUG; ANTIINFLAMMATORY AGENT;

BRAIN DAMAGE; BRAIN HEMORRHAGE; CLEFT LIP; CLEFT PALATE; CLINICAL TRIAL; CONGENITAL HEART MALFORMATION; CONGENITAL MALFORMATION; CROHN DISEASE; DRUG INFORMATION; EVIDENCE BASED MEDICINE; EYE TOXICITY; FALLOT TETRALOGY; FIRST TRIMESTER PREGNANCY; GASTROSCHISIS; GROWTH RETARDATION; HIGH RISK PREGNANCY; HUMAN; LOW BIRTH WEIGHT; META ANALYSIS; NECROTIZING ENTEROCOLITIS; NEURAL TUBE DEFECT; NONHODGKIN LYMPHOMA; NONHUMAN; OTOTOXICITY; PATIENT SAFETY; POSTMARKETING SURVEILLANCE; PREGNANT WOMAN; PREMATURITY; PRENATAL DRUG EXPOSURE; RETINA DISEASE; REVIEW; RHEUMATOID ARTHRITIS; RISK ASSESSMENT; RISK FACTOR; SMALL INTESTINE PERFORATION; SPONTANEOUS ABORTION; SYSTEMATIC REVIEW; SYSTEMIC LUPUS ERYTHEMATOSUS; TERATOGENESIS; TOXICITY TESTING; VITAMIN SUPPLEMENTATION; ARTHRITIS, RHEUMATOID; FEMALE; PREGNANCY; PREGNANCY COMPLICATIONS;

ANTI-INFLAMMATORY AGENTS; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; FEMALE; HUMANS; PREGNANCY; PREGNANCY COMPLICATIONS; PRODUCT SURVEILLANCE, POSTMARKETING;

EID: 33748559091     PISSN: 14786354     EISSN: None     Source Type: Journal    
DOI: 10.1186/ar1977     Document Type: Review

References (98)

1. Henshaw SK: Unintended pregnancy in the United States. Fam Plann Perspect 1998, 30:24-29.
2. Floyd RL, Dencoufle P, Hungerford DW: Alcohol use prior to pregnancy recognition. Am J Prev Med 1999, 17:101-107.
3. Scialli AR, Buelke-Sam JL, Chambers CD, Friedman JM, Kimmel CA, Polifka JE, Tassinari MS: Communicating risks during pregnancy: A workshop on the use of data from animal developmental toxicity studies in pregnancy labels for drugs. Birth Defects Res A Clin Mol Teratol 2004, 70:7-12.
4. Lo WY and Friedman JM: Teratogenicity of recently introduced medications in human pregnancy. Obstet Gynecol 2002, 100: 465-473.
5. Teo SK, Denny FH, Stirling DI, Thomas SD, Morseth S, Hoberman AM: Effects of thalidomide on reproductive function and early embryonic development in male and female New Zealand White rabbits. Birth Defects Res B 2004, 71:1-16.
6. Scott JR: Fetal growth retardation associated with maternal administration of immunosuppressive drugs. Am J Obstet Gynecol 1977, 128:668-676.
7. Reinisch JM, Simon NG, Karow WG, Glaudelman R: Prenatal exposure to prednisone in humans and animals retards intrauterine growth. Science 1978, 202:436-438.
8. Rayburn WF: Glucocorticord therapy for rheumatic diseases: Maternal, fetal, and breast-feeding considerations. Am J Reprod Immunol 1992, 28:138-140.
9. Fraser FC, Sajoo A: Teratogenic potential of corticosteroids in humans. Teratology 1995, 51:45-46.
10. Pradat P, Robert-Gnasia E, Di Tanna GL, Rosano A, Lisi A, Mastroiacovo P, Contributors to the MADRE database: First trimester exposure to corticosteroids and oral clefts. Birth Defects Res A Clin Mol Teratol 2003, 67:968-970.
11. Czeizel AE, Rockenbauer M: Population-based case-controls study of teratogenic potential of corticosteroids. Teratology 1997, 56:335-340.
12. Rodriguez-Pinilla E, Martinez-Frias ML: Corticosteroids during pregnancy and oral clefts: a case-control study. Teratology 1988, 58:2-5.
13. Carmichael SL, Shaw GM: Maternal corticosteroid use and risk of selected congenital anomalies. Amer J Med Genet 1999, 86:242-244.
14. Park-Wyllie L, Mazzotta P, Pastuszak A, Moretti ME, Beique L, Hunnisett L, Friesen MH, Jacobson S, Kasapinovic S, Chang D, et al.: Birth defects after maternal exposure to corticosteroids: prospective cohort study and meta-analysis of epidemiological studies. Teratology 2000, 62:385-392.
15. Aselton P, Jick H, Milunsky A, Hunter JR, Stergachis A: First trimester drug use and congenital disorders. Obstet Gynecol 1985, 65:451-455.
16. Ericson K, Kallen BAJ: Non-steroidal anti-inflammatory drugs in early pregnancy. Reprod Toxicol 2001, 15:371-375.
17. Barry WS: Ibuprofen overdose and exposure in utero: results from a postmarketing voluntary reporting system. Am J Med 1984,77:35-39.
18. Shaw GM, Todoroff K, Velie EM, Lammer EJ: Maternal illness, including fever and medication use as risk factors for neural tube defects. Teratology 1998, 57:1-7.
19. Torfs CP, Katz EA, Bateson TF, Lam PK, Curry CJR: Maternal medications and environmental exposures as risk factors for gastroschisis. Teratology 1996, 54:84-92.
20. Werler MM, Mitchell AA, Shapiro S: First trimester maternal medication use in relation to gastroschisis. Teratology 1992, 45:361-367.
21. Werler MM, Sheehan JE, Mitchell AA: Maternal medication use and risks of gastroschisis and small intestinal atresia. Am J Epidemiol 2002, 155:26-31.
22. Kallen BAJ, Olausson PO: Maternal drug use in early pregnancy and infant cardiovascular defect. Reprod Toxicol 2003, 17:255-261.
23. Nielsen GL, Sorensen HT, Larsen H, Pedersen L: Risk of adverse birth outcome and miscarriage in pregnant users of nonsteroidal anti-inflammatory drugs: population based observational study and case-control study. BMJ 2001, 322: 266-270.
24. Li D-K, Liu L, Odoul R: Exposure to non-steroidal anti-inflammatory drugs during pregnancy and risk of miscarriage: population based cohort study. BMJ 2003, 327:368-370.
25. Vermillion ST, Scardo JA, Lashus AG, Wiles HB: The effect of indomethacin toxolysis on fetal ductus arteriosus constriction with advancing gestational age. Am J Obstet Gynecol 1997, 177:256-259.
26. Kaplan BS, Restaino I, Raval DS, Gottlileb RP, Bernstein J: Renal failure in the neonate associated with in utero exposure to non-steroidal anti-inflammatory agents. Pediatr Nephrol 1994, 8:700-704.
27. Major CA, Lewis DF, Harding JA, Porto MA, Garite TJ: Tocolysis with indomethacin increasing the incidence of necrotizing enterocolitis in the low- birth-weight neonate. Am J Obstet Gynecol 1994, 170:102-106.
28. Baerts W, Fetter WP, Hop WC, Wallenburg HC, Spritzer R, Sauer PJ: Cerebral lesions in preterm infants after tocolytic indomethacin. Dev Med Child Neurol 1990, 32:910-918.
29. Tassinari MS, Cook JC, Hurtt ME: NSAIDs and developmental toxocity. Birth Defects Res B 2003, 68:3-4.
30. Milunsky A, Graef JW, Gaynor MF Jr: Methotrexate-induced congenital malformations. J Pediatr 1968, 72:790-795.
31. Del Campo M, Kosaki K, Bennett FC, Jones KL: Developmental delay in fetal aminopterin/methotrexate syndrome. Teratology 1999, 60:10-12.
32. Feldkamp M, Carey JC: Clinical teratology counseling and consultation case report: Low dose methotrexate exposure in the early weeks of pregnancy. Teratology 1993, 47:553-539.
33. Kozlowski RD, Steinbrunner JW, MacKenzie, Clough JD, Wilke WS, Segal AM: Outcome of first-trimester exposure to low-dose methotrexate in eight patients with rheumatic disease. Amer J Med 1990, 88:589-592.
34. Donnenfeld AE, Pastuszak A, Noah JS, Schick B, Rose NC, Koren G: Methotrexate exposure prior to and during pregnancy. Teratology 1994, 49:79-81.
35. Buckley LM, Bullaboy CA, Leichtman L, Marquez M: Multiple congenital anomalies associated with weekly low-dose methotrexate treatment of the mother. Arthritis Rheum 1997, 40:971-973.
36. Lewden B, Vial T, Elefant E, Nelva A, Calier P, Descotes J, and the French Network of Regional Pharmacovigilance Centers: Low dose methotrexate in the first trimester of pregnancy: results of a French collaborative study. J Rheumatol 2004, 31:2360-2365.
37. Hernandez-Diaz S, Werler MA, Walker Am, Mitchell AA: Folic acid antagonist during pregnancy and the risk of birth defects. N Engl J Med 2000, 343:1608-1614.
38. Willoughby CP, Truelove SC: Ulcerative colitis and pregnancy. Gut 1980,1:469-474.
39. Mogadam M, Dobbins WO III, Lorelitz BI, Ahmed SW: Pregnancy in inflammatory bowel disease: Effect of sulfasalazine and corticosteroids on fetal outcome. Gastroenterology 1981, 80: 72-27.
40. Nielsen OH, Andreasson B, Bondesen S, Jarnum S: Pregnancy in ulcerative colitis. Scand J Gastroenterol 1983, 18:735-742.
41. Hernandez-Diaz S, Werler MA, Walker AM, Mitchell AA: Neural tube defects in relation to folic acid antagonists during pregnancy. Am J Epidemiol 2001, 153: 961-968.
42. Moody GA, Probert C, Jayanthi V, Mayberry JF: The effects of chronic ill health and treatment with sulfasalazine on fertility amongst men and women with inflammatory bowel disease in Leicestershire. Int J Colorect Dis 1997, 12:220-224.
43. Norgard B, Czeizel AE, Rockenbauer M, Olsen J, Sorenson HT: Population-based case control study of the safety of sulfasalazine use during pregnancy. Ailment Pharmacol Ther 2001, 15:483-486.
44. Hoo JJ, Hadro TA, Von Behren P: Possible teratogenicity of sulfasalazine. N Engl J Med 1988, 318:1128.
45. Newman NM, Correy JF: Possible teratogenicity of sulfasalazine. Med J Aust 1983,1:528-529.
46. Craxi A, Pagliarello F: Possible embryotoxicity of sulfasalazine. Arch Intern Med 1980, 140:1674.
47. Chakravarty EF, Sanchez-Yamamoto D, Bush TM: The use of disease modifying antirheumatic drugs in women with rheumatoid arthritis of childbearing age: a survey of practice pattern and pregnancy outcomes. J Rheumatol 2003, 30:241-246.
48. De Santis M, Straface G, Cavaliere A, Carducci B, Caruso A: Paternal and maternal exposure to leflunomide: pregnancy and neonatal outcome. Ann Rheum Dis 2005, 64:1096-1097.
49. Chambers CD, Johnson DL, Macaraeg GR, Jones KL: Pregnancy outcome following early gestational exposure to leflunomide: the OTIS Rheumatoid Arthritis in Pregnancy Study [abstract]. Pharmacoepidemiol Drug Safety 2004, 13:S252.
50. Prakist A, Jarvis B: Leflunomide. A review of its use in active rheumatoid arthritis. Drugs 1999, 58:1137-1164.
51. Brent RL: Teratogen Update: reproductive risk of leflunomide (Arava): a pyrimidine synthesis inhibitor: counseling women taking leflunomide before or during pregnancy and men taking leflunomide who are contemplating fathering a child. Teratology 2001, 63:106-112.
52. Wolfe MS, Cordero JF: Safety of chloroquine in chemosupression of malaria during pregnancy. BMJ 1985, 290:1466-1467
53. Phillips-Howard PA, Wood D: The safety of antimalarial drugs in pregnancy. Drug Safety 1996, 14:131-145.
54. Sowunmi A, Fehintola FA, Ogundahunsi OA, Arowojolu AO, Oduola TM: Efficacy of chloroquine plus chloropheniramine in chloroquine-resistant falciparum malaria during pregnancy in Nigerian women: A preliminary study. J Obstet Gynecol 1998, 18:524-527.
55. Costedoat-Chalumeau N, Amoura Z, Huong du LT, Lechat P, Piette J-C: Safety of hydroxychloroquine in pregnant patients with connective tissue diseases. Review of the literature. Autoimmunity Rev 2005, 4:111-115.
56. Buchanan NM, Toubi E, Khamashta MA, Lima F, Kerslake S, Hughes GR: Hydroxychloroquine and lupus pregnancy: review of a series of 36 cases. Ann Rheum Dis 1996, 55:486-488.
57. Levy A, Vilea V, Cataldo M, Ramos RC, Duarte JL, Tura BR, Albuquerque EM, Jesus NR: Hydroxychloroquine (HCQ) in lupus pregnancies: double blind and placebo controlled study. Lupus 2001, 10:401-404.
58. Costedoat-Chalumeau N, Amoura Z, Duhaut P, Huong du LT, Sebbough D, Wechsler B, Vauthier D, Denjoy I, Lupoglazoff JM, Piette JC: Safety of hydroxycholorquine in pregnant patients with connective tissue diseases: a study of 133 cases compared with a control group. Arthritis Rheum 2003, 48:3207-3211.
59. Levy M, Buskila D, Gladman DD: Pregnancy outcome following first trimester exposure to chloroquine. Amer J Perinatol 1991, 8:174-178.
60. Parke AL, West B: Hydroxychloroquine in pregnant patients with systemic lupus erythematosus. J Rheumatol 1996, 23: 1715-1718.
61. Ostensen M, Ramseyu-Goldman R: Treatment of inflammatory rheumatic disorders in pregnancy. Drug Safety 1998, 19:389-410.
62. Parke AL: Antimalarial drugs, systemic lupus erythematosus and pregnancy. J Rheumatol 1998, 15:607-610.
63. Lindquist NG, Ullberg S: The melanin affinity of chloroquine and chlorpromazine studied by whole body autoradiography. Acta Pharmacol Toxicol 1972, 31(suppl 2):1-31.
64. Hart CW, Nauton RF: The ototoxicity of chloroquine phosphate. Arch Otolaryngol 1964, 80:407-412.
65. Penn I, Makowski EL, Harris P: Parenthood following renal transplantation. Kidney Intl 1980, 18:221-233.
66. Marushak A, Weber TN, Bock J, Birkeland SA, Hanson HE, Klebe J, Kristoffersen K, Rasmussen K, Olgaard K: Pregnancy following kidney transplantation. Acta Obstet Gynecol Scand 1986, 65:557-559.
67. Brown JH, Maxwell AP, McGowan MG: Outcome of pregnancy following renal transplantation. Ire J Med Sci 1991, 160:255-256.
68. Cararach V, Monleon FJ: Pregnancy after renal transplantation: 25 years experience in Spain. Br J Obstet Gynecol 1993, 100: 122-125.
69. Haugen G, Fauchald P, Sodal G, Leivestad T, Moe N: Pregnancy outcome in renal allograft recipients in Norway. Acta Obstet Gynecol Scand 1994, 73:541-546.
70. Alstead EM, Ritchie JK, Lennard-Jones JE, Farthing MJ, Clark ML: Safety of azathioprine in pregnancy in inflammatory bowel disease. Gastroenterology 1990, 99:443-446.
71. Ramsey-Goldman R, Mientus JM, Kutzer JE, Mulvihill JJ, Medsger TA Jr: Pregnancy outcome in women with systemic lupus erythematosis treated with immunosuppressive drugs. J Rheumatol 1993, 20:1152-1157.
72. Martinez-Rueda JO, Arce-Salinas CA, Kraus A, Alcocer-Varela J, Alarcon-Segovia D: Factors associated with fetal losses in severe systemic lupus erythematosis. Lupus 1996, 5:113-119.
73. Kallen B: Drug treatment of rheumatic diseases during pregnancy. The teratologenicity of antirtheumatic drugs - what is the evidence. Scand J Rheumatol Suppl 1998, 107:119-124.
74. Moskovitz DN, Bodian C, Chapman ML, Marion JF, Rubin PH, Scherl E, Present DH: The effect on the fetus of medications used to treat pregnant inflammatory bowel-disease patients. Am J Gastroenterol 2004, 99:656-661.
75. Gaughan WJ, Moritz MK, Radomski JS, Burke JF Jr, Armenti VT: National Transplantation Pregnancy Registry: Report on outcomes in cyclosporine treated female kidney transplant recipients; with an interval from transplant to pregnancy of greater than five years. Am J Kid Dis 1996, 28:266-269
76. Armenti VT, McGrory CH, Cater JR, Radomski JS, Moritz MJ: Pregnancy outcomes in female transplant recipients. Transplantation Proc 1998, 30:1732-1734.
77. Armenti VT, Moritz MJ, Davison JM: Drug safety issues in pregnancy following transplantation and immunosuppression. Drug Safety 1998, 19:219-232.
78. Toma H, Tanabe K, Tokumoto T, Kobayashi C, Yagisawa T: Pregnancy in women receiving renal dialysis or transplantation in Japan: a nationwide survey. Nephrol Dial Transplant 1999, 14: 1511-1516.
79. Bar Oz B, Hackman R, Einarson T, Koren G: Pregnancy outcome after cyclosporine therapy during pregnancy: a meta-analysis. Transplantation 2001, 71:1051-1055.
80. Tendron-Franzin A, Gouyon JB, Guignard JP, Decramer S, Justrabo E, Gilbert T, Semama DS: Long-term effects of in utero exposure to cyclosporine A on renal function in the rabbit. J Am Soc Nephrol 2004, 15:2687-2693.
81. Armenti VT: Immunosuppression and teratology: evolving guidelines. J Am Soc Nephrol 2004, 15:2759-2760.
82. Shotton D, Monie IW: Possible teratogenic effect of chlorambucil on a human fetus. JAMA 1963, 186:180-181.
83. Steege JF, Caldwell DS: Renal agenesis after first trimester exposure to chlorambucil. Southern Med J 1980, 73:1414-1415.
84. Monie IW: Chlorambucil induced abnormalities of the urogenital system of rat fetuses. Anat Rec 1961, 139:145.
85. Vaux KK, Kahole NCO, Jones KL: Cyclohosphamide, methotrexate and cytarabine embryopathy: Is apoptosis the common pathway? BDRA Clin Mol Teratol 2003, 67:403-408.
86. Clowse M, Magder L, Petri M: Cyclophosphamide for lupus during pregnancy. Lupus 2005, 14:593-597.
87. Kart Koseoglu H, Yucel A, Kunefeci G, Ozdemir F, Duran H: Cyclophosphamide therapy in a serious case of lupus nephritis during pregnancy. Lupus 2001, 10:818-820.
88. Sills E, Perloe M, Tucker M, Kaplan C, Palerma G: Successful ovulation induction, conception, and normal delivery after chronic therapy with etanercept: a recombinant fusion anticytokine treatment for rheumatoid arthritis. Am J Reprod Immunol 2001, 46:366-368.
89. Chambers CD, Johnson DL, Jones KL, and the OTIS Collaborative Research Group: Pregnancy outcome in women exposed to anti-TNF-alpha medications: the OTIS Rheumatoid Arthritis in Pregnancy Study [abstract]. Dermatology 2005, 152:205.
90. Katz JA, Antoni C, Keenan GF, Smith DE, Jacobs SJ, Lichtenstein GR: Outcome of pregnancy in women receiving infliximab for the treatment of Crohn's disease and rheumatoid arthritis. Am J Gastroenterol 2004, 99:2385-2392.
91. Mahadevan U, Kane S, Sandborn J, Cohen RD, Hanson K, Terdiman JP, Binion DG: Intentional infliximab use during pregnancy for induction or maintenance of remission in Crohn's disease. Aliment Pharmacol Ther 2005, 21:733-738.
92. Vesga L, Terdiman JP, Mahadevan U: Adalimumbab use in pregnancy. Gut 2005, 54:890-891.
93. Orozco C, Dao K, Cush JJ, Kavanaugh A: Safety of TNF-inhibitors during pregnancy in patients with inflammatory arthritis [abstract). Arthritis Rheum 2005, Suppl:22-23.
94. Herold M, Schnohr S, Bittrish H: Efficacy and safety of a combined rituximab chemotherapy during pregnancy. J Clin Oncol 2001, 19:3439.
95. Kimby E, Sverrisdottir A, Elinder G: Safety of rutiximab therapy during the first trimester of pregnancy: a case history. Eur J Haematol 2004, 72:292-295.
96. Guidance for Industry: Establishing Pregnancy Exposure Registries [http://www.fda.gov/CBER/gdlns/pregexp.htm]
97. Chambers CD, Braddock SR, Briggs GG, Einarson A, Johnson YR, Miller RK, Polifka. JE, Robinson LK, Stepanuk, K, Jones KL: Post marketing surveillance for human teratogenicity: a model approach. Teratology 2001, 64:252-261.
98. OTIS: Arthritis and Pregnancy [http://www.raandpregnancy.org]